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Edited by Lukas HuberAbstract The b-catenin/Tcf complex is a downstream eﬀector
of the Wnt signalling pathway. It is a transcription complex,
which activates gene expression and contributes to proliferation
and tumor progression. Tcf1 in complex with b-catenin is able to
activate b-catenin-dependent gene expression. We demonstrate
that expressed Bcr is able to bind the transcription factor Tcf1
to disrupt the Tcf1/b-catenin complex. Phosphorylation of Bcr
by the tyrosine kinase pp60src can lead to dissociation of the
transcriptionally inactive Bcr/Tcf1 complex. Thus two indepen-
dent mechanisms may regulate Tcf/b-catenin-mediated tran-
scription via Bcr: binding to b-catenin as we have previously
shown and to Tcf1 as shown here.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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pathway1. Introduction
The Wnt signalling pathway mediates the expression of
numerous genes via the transcriptionally active T cell factor
(Tcf)/b-catenin or lymphoid enhancer factor (Lef)/b-catenin
complex, which regulates proliferation and tumor progression
[1]. b-catenin exists in a membrane-associated, cytoplasmic
and nuclear pool and regulates E-cadherin-mediated adhesion
of epithelial cells as well as Tcf-dependent gene expression
[2,3]. The Tcf/Lef transcription factor family in mammals con-
sists of four members Tcf1, Tcf3, Tcf4 and Lef1, whereby Tcf1
is mainly expressed in T lymphocytes [1]. The Tcf family mem-
bers exist as splice variants [4]. For Tcf1 ﬁve splice variants
Tcf1A to Tcf1E have been described. A predominant in vivo
isoform of Tcf1 is Tcf1B, which lacks internal sequences
[5,6]. Drosophila melanogaster and the Caenorhabditis elegans
code for one Tcf gene only [7,8].
Little is known about the regulatory mechanism of the Tcf1/
b-catenin-mediated gene expression in normal and tumor cells.
Negative regulation of Tcf1-dependent gene expression has
been described for splice variants of Tcf1 lacking the N-termi-
nal b-catenin binding site, and in some cases by proteins that
bind Tcf1, such as Groucho-related proteins [9,10]. Tcf1/b-
catenin-dependent transcription can also be mediated by the
Lef1 promotor [11].*Corresponding author. Fax: +41 44 634 49 67.
E-mail address: moelling@immv.unizh.ch (K. Moelling).
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.01.034It has been suggested that alterations in regulation of Tcf1/b-
catenin-dependent transcription could inﬂuence tumor pro-
gression. Activation of the Tcf1-speciﬁc promotor element
was observed in epithelial tumor cells [12]. Strong upregulation
of the tumor suppressor methylthioadenosine phosphorylase
(MTAP) in colon carcinoma is controlled by the Tcf1/b-cate-
nin complex [13]. Gynecological cancers show a mutated
and/or overexpressed Tcf1 [14]. Expression of Tcf1 is upregu-
lated along with the lymphoid kinase p56lck, which is also
expressed in colorectal cancer cell lines [15].
In this work, we analyzed the interaction of the multidomain
protein Bcr (breakpoint cluster region) with Tcf1. We have
shown recently, that Bcr can act as a negative regulator of
Tcf/b-catenin-mediated gene target c-myc via binding to b-
catenin [16]. Bcr has been described as a negative regulator
of Bcr-Abl via its serine–threonine kinase activity and its bind-
ing to c-Myc [17–19]. The binding of Bcr to Myc is thought to
destabilize the protein Myc. Furthermore, the inﬂuence of the
serine–threonine kinase activity of Bcr on the Ras-Raf-MEK-
ERK pathway has been investigated previously. It was found
that the complex of Bcr with AF6 negatively regulates Ras-
dependent Erk phosphorylation [20].
We show here that Bcr has a negative regulatory eﬀect on the
Tcf1/b-catenin complex, leads to its disruption and determines
the ratio between the transcriptionally inactive Tcf1/Bcr and
transcriptionally active Tcf1/b-catenin complex. Additionally,
it is shown that the Src kinase activity inhibits Tcf1/Bcr com-
plex formation. Based on our results, it is conceivable that
Src-mediated tyrosine phosphorylation of the negative regula-
tor Bcr leads to dissociation of the Tcf1/Bcr complex. This lib-
erates Tcf1, making it available for binding to b-catenin. This
is supported by Src-mediated tyrosine phosphorylation, thus
allowing Tcf1/b-catenin-dependent gene expression.2. Materials and methods
2.1. Plasmids
BcrWT was a kind gift of G. Radziwill (Institute of Medical Virol-
ogy, University of Zurich) [20]. Tcf1B was a gift from H.C. Clevers
(Utrecht University, Utrecht, NL) [5]. Src mutant Y527F was obtained
from Upstate (Virginia, USA).
2.2. Antibodies used for immunoprecipitation and immunoblots
Used method were described elsewhere [20]. Primary antibodies used
were rabbit anti-Bcr (N-20, C-20), anti-Src (SRC 2), mouse anti-b-cate-
nin (E-5), goat anti-Tcf1 (H-18), goat anti-Tcf4 (C-19), goat anti-actin
(I-19) (Santa Cruz, CA, USA) and mouse anti-pTyr (4G10) (Upstate).
Secondary antibodies used were donkey anti-rabbit, anti-goat and
sheep anti-mouse horseradish peroxidase-conjugated IgG (Amersham,
Otelﬁngen, Switzerland).blished by Elsevier B.V. All rights reserved.
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The media were supplemented with 10% fetal bovine serum, penicil-
lin and streptomycin. Transfections were performed using Lipofectin
(Invitrogen, Basel, Switzerland) according to the recommended proce-
dure.Fig. 2. Eﬀect of Bcr on Tcf1/b-catenin complex formation (A)
Overexpressed Bcr can bind to Tcf1B and reduce binding of Tcf1B
to endogenous b-catenin in HEK293 cells (lane 1). Endogenous level of
Bcr permit the Tcf1B/b-catenin complex (lane 2). Tcf1B was detected
by IP or IB in DL. * equal IgGL. Protein expression of Bcr and
b-catenin were analyzed by IB in DL. (B) Increasing levels of expressed
Bcr competes out endogenous b-catenin from endogenous Tcf1 (lanes
2–4: 1, 3, 5 lg). Only endogenous Bcr permitted the b-catenin/Tcf1
complex (lane 1). Protein expression of Bcr, b-catenin and Tcf1 were
analyzed by IB in DL. (C) Increasing levels of expressed Bcr does not
inﬂuence the Tcf4/b-catenin complex formation in HEK293T cells
(lanes 2–3: 1, 3 lg). Protein expression of Bcr, b-catenin and Tcf4 were
analyzed by IB in DL.3. Results and discussion
Tcf1 is a known T-lymphocyte-speciﬁc transcription factor.
It is expressed in various tissues and cell-types including liver,
kidney, pancreas, digestive tract, neoplastic T-lineage lympho-
cytes, colorectal epithelial tumor cells and liver adenomas [21–
25]. In a ﬁrst step the expression of transcription factor Tcf1
was analyzed here in the mammalian cell lines such as
HEK293, HEK293T, Cos7, HeLa, NIH3T3. A pronounced
expression was detected in HEK293T cells (data not shown),
which were therefore used as biological system. Also previous
studies have shown expression of Tcf1 in HEK293T cells [12].
We observed complex formation of endogenous Bcr and Tcf1
in HEK293T cells (Fig. 1A). In contrast, binding of Bcr to
Tcf4, a ubiquitously expressed transcription factor of the Tcf
family, was not detectable in HEK293T cells (Fig. 1B). Tcf1
and Tcf4 are related transcription factors sharing the same
b-catenin binding domain and DNA binding site, but may dif-
fer in their binding properties to Bcr.
Binding of Bcr to Tcf1 raised the question of how Bcr would
aﬀect Tcfs in a general complex with b-catenin. Previous stud-
ies have shown binding of Bcr to b-catenin [16] that may
sequester Bcr and prevent complex formation with the tran-
scription factors Tcf1 or Tcf4. We analyzed the Tcf1/b-catenin
and Tcf4/b-catenin complex formation with and without over-
expression of Bcr (Fig. 2A–C). First we expressed the predom-
inant in vivo isoform of Tcf1, P45Tcf1B, with Bcr in HEK293
cells which did not result in a Tcf1B/b-catenin complex
(Fig. 2A, lane 1). Only the endogenous levels of Bcr permit
the Tcf1B/b-catenin complex (Fig. 2A, lane 2). Increased
expression of Bcr was analyzed with the endogenous Tcf1/b-
catenin and Tcf4/b-catenin complex formation in HEK293T
cells. Bcr was not able to displace Tcf4 from b-catenin,Fig. 1. Bcr interacts with Tcf1 but not with Tcf4 in vivo (A).
Co-precipitation of endogenous Bcr with Tcf1 in HEK293T cells. Cell
lysates were immunoprecipitated (IP) with anti-Tcf1 antibody (lane 3),
anti-Bcr antibody (lane 2) and, as control, with anti-actin antibody
(lane 1). The samples were immunoblotted (IB) with anti-Bcr antibody.
Protein expression levels of Bcr and Tcf1 were analyzed by IB in direct
lysate (DL). (B) Tcf4 is not a binding partner of Bcr in HEK293T cells.
IB with anti-Tcf4 antibody (lane 3), anti-Bcr antibody (lane 2) and, as
control (co), with anti-actin antibody (lane 1). Protein expression levels
of Bcr and Tcf4 were analyzed by IB in DL.whereas Bcr dissociated the Tcf1/b-catenin complex (Fig. 2B,
C). Thus expression levels of suﬃcient levels of Bcr can seques-
ter Tcf1 from b-catenin, so that Tcf1/b-catenin-mediated gene
expression would be impaired.Fig. 3. Regulation of the endogenous Bcr/Tcf1 complex formation in
HEK293T cells by expression on the constitutive active Src(Y527F)
mutant was increased expressed (lanes 3–4: 1, 3 lg). Cell lysates were
IP with anti-Tcf1 antibody and, as control, with anti-actin antibody.
The Tcf1/Bcr complex is only detectable in the absence of the
Src(Y527F) mutant (lane 2).
Fig. 4. Regulation of the Tcf1/Bcr and Tcf1/b-catenin complex formation in cells with high level of Bcr (A), normal conditions (B) and pp60Src
expression (C). A complex of b-catenin and Tcf1 allows b-catenin-dependent gene transcription. A high level of Bcr can inhibit the Tcf1/b-catenin-
mediated transcription (A). The tyrosine kinase pp60Src can activate the b-catenin-dependent transcription through tyrosine phosphorylation of Bcr
and b-catenin (C).
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mutant, Src(Y527F), with a constitutively active tyrosine ki-
nase, on the Tcf1/Bcr complex formation (Fig. 3). Enhanced
pp60src activity has been shown to increase the growth rates
of cells, to reduce cell adhesion, and to augment metastatic po-
tential of cells [26,27]. It is known that pp60src can act as antag-
onist of b-catenin-mediated cell adhesion and as a promotor of
b-catenin-dependent gene transcription via tyrosine phosphor-
ylation of b-catenin [28]. pp60src phosphorylates b-catenin on
Y86 and Y654. Phosphorylation of Y654 induced association
to the transcription factor TATA-binding protein (TBP) [29].
The binding of Tcf4, which has a similar binding site of Tcf1,
with b-catenin is not aﬀected by phosphorylation of Y86 or
Y654. It is an essential function of tyrosine phosphorylated
b-catenin in complex with Tcf4 to allow their binding to the
promotors of Wnt-response genes and activation of transcrip-
tion. This may also be the case with Tcf1 in complex with b-
catenin phosphorylation by Src tyrosine kinase (Fig. 4C). The
recent observation that the constitutively active Src mutant,
Src(Y527F), exists in a small subset of advanced human colon
cancers [30] suggests that Src(Y527F) may contribute to cancer.
As can be seen the Src kinase activity of constitutively active
Src(Y527F) induced phosphorylation of Bcr, which abolished
the endogenous Tcf1/Bcr complex in HEK293T cells (Fig. 3,
lanes 3–4). In direct lysates Src-induced tyrosine phosphoryla-
tion of Bcr can be detected (Fig. 3, lanes 3–4). Our ﬁndings sug-
gest that a high level of pp60src activity leads to a reduced
formation of the Tcf1/Bcr complex, while the b-catenin/Tcf1
complex is favored allowing transcriptional activity. Activation
of b-catenin/Tcf1-dependent gene expression may support tu-
mor progression (Fig. 4C).
Self-renewal of hematopoietic stem cells, progenitor cells
and tumor cells show activation of the b-catenin pathway,
which results in the translocation of b-catenin to the nucleus
[31–33]. Elevated levels of nuclear b-catenin were described
in granulocyte-macrophage precursor cells from patients with
chronic myelogenous leukemia, CML, which enhance the
self-renewal activity and leukemic potential [34,35]. The b-
catenin/Tcf complex formation can up-regulate transcription,
e.g., of the oncogene myc [36]. In cells expressing the oncopro-
tein Bcr-Abl, the ratio of Bcr-Abl oncoprotein to the Bcr pro-tein is proposed to be a major factor that determines the
aggressiveness of the leukemia [17]. Bcr reduces the Bcr-Abl-
induced pathogenic eﬀects [17,37]. Previously studies have
shown that increased Bcr dosage correlated with a reduction
of the c-Myc expression level [17], while high expression of c-
Myc in CML contributes to disease progression [38]. We have
shown previously, using endogenous levels of Bcr, that Bcr
binds b-catenin and is a negative regulator of Myc expression
[16]. Higher levels of Bcr allow Bcr/Tcf1 complex formation as
shown here. Thus Bcr can form a complex with b-catenin and
Tcf1. Low levels of Bcr as described in Bcr-Abl tumor cells
may allow b-catenin/Tcf1-mediated eﬀects, supporting the role
of Bcr as tumor suppressor.
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